What are the indications, selection criteria, and bronchoscopic treatment options for non‑surgical lung volume reduction in patients with severe emphysema?

Non-Surgical Lung Volume Reduction

For patients with severe emphysema and significant hyperinflation refractory to optimal medical therapy, bronchoscopic lung volume reduction using endobronchial valves should be considered as the primary non-surgical intervention, particularly in those with heterogeneous emphysema and absence of collateral ventilation. 1, 2

Patient Selection Criteria

The success of bronchoscopic lung volume reduction (BLVR) hinges on meticulous patient selection. Ideal candidates must meet the following criteria:

Physiologic Requirements

• Severe emphysema with FEV1 typically <45% predicted
• Significant hyperinflation with elevated residual volume
• Persistent dyspnea despite maximal medical therapy including long-acting bronchodilators and pulmonary rehabilitation
• Post-rehabilitation exercise capacity that remains limited 1

Anatomic Requirements (Critical for Success)

• Heterogeneous emphysema distribution on high-resolution CT, with clear target lobe identification
• Complete interlobar fissure integrity (>90% intact)
• Absence of collateral ventilation between target and adjacent lobes—this is the single most important predictor of success 2, 3
• Assessment via Chartis system or quantitative CT analysis 3

Exclusion Criteria (Contraindications)

Absolute contraindications include:

• FEV1 ≤20% predicted with either homogeneous emphysema on HRCT or DLCO ≤20% predicted (associated with higher mortality than medical management) 1
• Active pulmonary infection
• Significant pulmonary hypertension
• Recent myocardial infarction

Bronchoscopic Treatment Options

Endobronchial Valves (EBVs) - First-Line BLVR

Endobronchial valves represent the most extensively studied and effective BLVR technique with over 25,000 cases performed worldwide 2, 4. Two primary systems exist:

• Zephyr valves: One-way valves placed bronchoscopically to achieve complete lobar occlusion
• Spiration valves: Alternative valve system with similar mechanism

Mechanism: EBVs induce atelectasis of the most diseased lung segments while allowing healthier parenchyma to expand, improving respiratory mechanics and reducing hyperinflation 2, 3

Evidence: Landmark RCTs demonstrated statistically significant improvements in:

• FEV1 (clinically meaningful increases)
• 6-minute walk distance
• Quality of life (SGRQ scores)
• Comparable benefits to surgical LVRS but with reduced morbidity and mortality 1, 2

Nitinol Coils

Two multicenter trials showed:

• Increases in 6-minute walk distance compared to usual care
• Smaller improvements in FEV1 and quality of life
• Less robust evidence than EBVs 1

Ineffective or Harmful Approaches (Avoid)

• Bronchial stents: Prospective studies showed no effectiveness 1
• Lung sealant: Caused significant morbidity and mortality 1

Complications and Management

Pneumothorax (Most Common Serious Complication)

• Occurs in approximately 26% of patients receiving EBVs 2
• Critical nuance: Pneumothorax paradoxically indicates successful lobar occlusion and predicts favorable long-term outcomes 2
• Requires chest tube placement in roughly 50% of cases
• Patients must be counseled about this risk pre-procedure

Other Complications

• Valve migration
• Airway infections
• Hemoptysis (usually self-limiting)
• COPD exacerbations 3

Clinical Algorithm for BLVR Candidacy

Step 1: Confirm severe emphysema with persistent symptoms despite:

• Optimal bronchodilator therapy (LABA/LAMA combination)
• Completed pulmonary rehabilitation program
• Smoking cessation (mandatory)

Step 2: Obtain high-resolution chest CT to assess:

• Emphysema distribution (heterogeneous vs. homogeneous)
• Target lobe identification
• Fissure integrity quantification

Step 3: Exclude high-risk patients:

• FEV1 ≤20% with homogeneous emphysema or DLCO ≤20%
• Significant comorbidities (severe pulmonary hypertension, recent MI)

Step 4: Assess collateral ventilation:

• Chartis system evaluation during bronchoscopy, OR
• Quantitative CT fissure analysis

Step 5: If absent collateral ventilation confirmed → Proceed with EBV placement

Comparison to Surgical LVRS

The GOLD guidelines note that surgical LVRS improves survival in patients with upper-lobe emphysema and low post-rehabilitation exercise capacity 1. However, BLVR with EBVs offers:

• Lower morbidity and mortality compared to surgery
• Reversibility (valves can be removed if complications occur)
• Suitable for patients who are not surgical candidates due to age or comorbidities 2, 5

Important Caveats

The GOLD guidelines emphasize that additional data are needed to define optimal patient populations and compare long-term durability of BLVR improvements to surgical LVRS 1. However, given the lower risk profile and reversibility, EBVs should be strongly considered before surgical options in appropriately selected patients.

Bridge to transplantation: BLVR can serve as a bridging therapy for lung transplant candidates, improving symptoms and function while awaiting donor organs 5.

The evidence supporting EBVs in patients with both heterogeneous and homogeneous emphysema shows mixed outcomes, with heterogeneous disease demonstrating more consistent benefit 1. Therefore, prioritize patients with clear heterogeneous distribution and intact fissures for optimal results.